Gabapentin Solution
Product Images NDC 31722-069

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 31722-069). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottel-carton (Bottel Carton)

FDA Label Image

Bottel-label (Bottel Label)

Bottel-label (Bottel Label)
This text appears to be the description of a medication called Gabapentin Oral Solution, manufactured by Camber Pharmaceuticals. The solution contains 250 mg of gabapentin per 5 mL. It is recommended to store the solution refrigerated between 2°C to 8°C (36°F to 46°F). The medication guide should be given to each patient. For more information, the medication guide can be found at http://camberpharma.com/medication-guides. It is important to keep this medication and all drugs out of the reach of children. The U.S. contact number for Camber Pharmaceuticals is 1-866-495-1995. Manufactured by Annora Pharma Pvt. Ltd. in Sangareddy, Telangana, India. Manufactured for Camber Pharmaceuticals, Inc. in Piscataway, NJ.*
FDA Label Image

Camberlogo---2 (Camberlogo 2)

FDA Label Image
FDA Label Image

Gabapentios-fig1 (Gabapentios Fig1)

Gabapentios-fig1 (Gabapentios Fig1)
The text provided appears to be a table showing the mean pain score over a 8-week period. The table includes two periods: a 4-week dose titration period and a 4-week fixed dose period. The treatment options being tested are a placebo and gabapentin at a dose of 3600mg per day. The baseline pain score is not visible, but the subsequent weeks are labeled from 1 to 8.*
FDA Label Image

Gabapentios-fig2 (Gabapentios Fig2)

Gabapentios-fig2 (Gabapentios Fig2)
This text appears to be a table or graph showing the duration, dosage, and pain score for a study involving three different treatments: placebo, 1800 mg/day of gabapentin, and 2400 mg/day of gabapentin. The study seems to have been conducted over a period of several weeks, and there is a column indicating the baseline pain score. However, without the actual values or clearer context, it is difficult to provide a more detailed description.*
FDA Label Image

Gabapentios-fig3 (Gabapentios Fig3)

Gabapentios-fig3 (Gabapentios Fig3)
This text appears to be showing the proportions of responders (patients with a >50% reduction in pain score) at the endpoint of controlled Postherpetic Neuralgia (PHN) studies. The percentages range from 100% to 0% in decreasing intervals of 10%. The text also mentions "Study 1" and "Study 2" with corresponding percentages and dosages of "PBO GBP 3600," "GBP 1800," and "GBP 2400." There are also significant p-values indicated as "*p< 001" and "**p< 0.001."*
FDA Label Image

Gabapentios-fig4 (Gabapentios Fig4)

FDA Label Image

Gabapentios-structure (Gabapentios Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.